ERK5 Signalling and Resistance to ERK1/2 Pathway Therapeutics: The Path Less Travelled?

Abstract excerpt

mutations and such cells are addicted to the activity of these mutant oncoproteins. As a result three different BRAF inhibitors (BRAFi) have now been approved for BRAFV600E/K- mutant melanoma and have transformed the treatment of this disease. Despite this, clinical responses are typically transient as tumour cells develop resistance. These resistance mechanisms frequently involve reinstatement of ERK1/2...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Computational Drug Discovery Methods
• Share to Cytokine Signaling Pathways and Interactions
• Share to Melanoma and MAPK Pathways